Shearman & Sterling represented Concord Medical Services Holdings Limited (“Concord Medical”) in the acquisition of an indirect interest of 19.98% in The University of Texas MD Anderson Cancer Center Proton Therapy Center (the “Proton Therapy Center”). Upon completion of the acquisition, Concord Medical is now the second largest owner of the MD Anderson Proton Therapy Center, behind MD Anderson Cancer Center.
Listed on the New York Stock Exchange, Concord Medical is a leading specialty hospital management solution provider and operator of the largest network of radiotherapy and diagnostic imaging centers in China.
The Proton Therapy Center is an affiliate of The University of Texas MD Anderson Cancer Center. Opened in 2006, the Proton Therapy Center was the fourth proton treatment center in the US. Since its opening, it has treated more than 4,000 patients, accounting for 15% of the total number of patients who received proton treatment nationally.
The following Shearman & Sterling team advised Concord Medical in the transaction: partners Shuang Zhao (Hong Kong-Capital Markets) andLorna Chen (Hong Kong-Investment Funds), counsel Pang Lee (Hong Kong-Investment Funds) and associates Yi Zhang (Hong Kong-Mergers & Acquisitions), Tina Li and Liyong Xing (both Hong Kong-Investment Funds).
